JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:2229-2236, doi:10.1016/j.jacc.2005.12.073 (Published online 12 May 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Briand, M.
Right arrow Articles by Pibarot, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Briand, M.
Right arrow Articles by Pibarot, P.

Metabolic Syndrome Negatively Influences Disease Progression and Prognosis in Aortic Stenosis

Martin Briand, MS*,1, Isabelle Lemieux, PhD*, Jean G. Dumesnil, MD, FACC*, Patrick Mathieu, MD*, Amélie Cartier, MS*, Jean-Pierre Després, PhD, FAHA*,{dagger},3, Marie Arsenault, MD*,4, Jacques Couet, PhD*,4 and Philippe Pibarot, DVM, PhD, FACC*,2,*

* Laval Hospital Research Center/Québec Heart Institute, Department of Medicine, Laval University, Québec, Canada
{dagger} Division of Kinesiology, Department of Social and Preventive Medicine, Laval University, Québec, Canada


Figure 1
View larger version (59K):

[in a new window]
  		Figure 1 Rate of progression of aortic valve area (AVA) with presence (orange bars) or absence (blue bars) of age ≥70 years, male gender, hypertension (HPT), obesity, history of hypercholesterolemia (Hyperchol), history of smoking, diabetes, and metabolic syndrome (MS).

 

Figure 2
View larger version (30K):

[in a new window]
  		Figure 2 Rate of progression of aortic valve area (AVA) among the two groups separated according to the median value of the Framingham score in patients with metabolic syndrome (MS) (orange bars) and those without MS (blue bars). {dagger}Significant difference versus group 2 (p < 0.05).

 

Figure 3
View larger version (30K):

[in a new window]
  		Figure 3 Rate of progression of aortic valve area (AVA) among the two groups separated according to the presence or absence of statin therapy in patients with metabolic syndrome (MS) (orange bars) and those without MS (blue bars). *Significant difference versus group 1 (p < 0.05); {dagger}significant difference versus group 2 (p < 0.05).

 

Figure 4
View larger version (15K):

[in a new window]
  		Figure 4 Kaplan-Meier analysis of event-free survival in 40 patients with metabolic syndrome (MS) compared with 65 patients without MS.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.